Related Experiment Video
Updated: Jan 6, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis
Karla Solo1,2, Shahar Lavi3, Conrad Kabali4
1Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Insights
Adding ticagrelor or clopidogrel to aspirin significantly reduces saphenous vein graft failure after coronary artery bypass graft surgery. Tailor dual antiplatelet therapy based on patient outcomes and drug profiles.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Surgical Outcomes
Background:
- Saphenous vein graft failure is a significant complication after coronary artery bypass graft (CABG) surgery.
- Oral antithrombotic drugs are used to prevent graft failure, but optimal therapy remains debated.
Purpose of the Study:
- To assess the comparative effectiveness of different oral antithrombotic drugs in preventing saphenous vein graft failure post-CABG.
- To evaluate the safety profiles of these antithrombotic therapies regarding major bleeding, myocardial infarction, and death.
Main Methods:
- A systematic review and network meta-analysis of randomized controlled trials.
- Searched multiple databases (Medline, Embase, Web of Science, CINAHL, Cochrane Library) up to January 25, 2019.
- Included trials investigating oral antiplatelets or anticoagulants for preventing saphenous vein graft failure in CABG patients.
Main Results:
- 20 randomized controlled trials with 4803 participants were included.
- Dual antiplatelet therapy with aspirin plus ticagrelor or aspirin plus clopidogrel showed moderate certainty evidence of reducing graft failure compared to aspirin monotherapy.
- No significant differences in major bleeding, myocardial infarction, or death were observed among the antithrombotic therapies.
Conclusions:
- Adding ticagrelor or clopidogrel to aspirin provides a significant absolute benefit in preventing saphenous vein graft failure post-CABG.
- Personalized dual antiplatelet therapy selection is recommended, balancing efficacy and safety for individual patients.
Objective:
To assess the effects of different oral antithrombotic drugs that prevent saphenous vein graft failure in patients undergoing coronary artery bypass graft surgery.
Design:
Systematic review and network meta-analysis.
Data Sources:
Medline, Embase, Web of Science, CINAHL, and the Cochrane Library from inception to 25 January 2019. ELIGIBILITY CRITERIA: for selecting studies Randomised controlled trials of participants (aged ≥18) who received oral antithrombotic drugs (antiplatelets or anticoagulants) to prevent saphenous vein graft failure after coronary artery bypass graft surgery.
Main Outcome Measures:
The primary efficacy endpoint was saphenous vein graft failure and the primary safety endpoint was major bleeding. Secondary endpoints were myocardial infarction and death.
Results:
This review identified 3266 citations, and 21 articles that related to 20 randomised controlled trials were included in the network meta-analysis. These 20 trials comprised 4803 participants and investigated nine different interventions (eight active and one placebo). Moderate certainty evidence supports the use of dual antiplatelet therapy with either aspirin plus ticagrelor (odds ratio 0.50, 95% confidence interval 0.31 to 0.79, number needed to treat 10) or aspirin plus clopidogrel (0.60, 0.42 to 0.86, 19) to reduce saphenous vein graft failure when compared with aspirin monotherapy. The study found no strong evidence of differences in major bleeding, myocardial infarction, and death among different antithrombotic therapies. The possibility of intransitivity could not be ruled out; however, between-trial heterogeneity and incoherence were low in all included analyses. Sensitivity analysis using per graft data did not change the effect estimates.
Conclusions:
The results of this network meta-analysis suggest an important absolute benefit of adding ticagrelor or clopidogrel to aspirin to prevent saphenous vein graft failure after coronary artery bypass graft surgery. Dual antiplatelet therapy after surgery should be tailored to the patient by balancing the safety and efficacy profile of the drug intervention against important patient outcomes.
Study Registration:
PROSPERO registration number CRD42017065678.
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Venous Thrombosis III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Angina IV: Management

